Haisco Pharmaceutical Group Co., Ltd.

SZSE:002653 Stock Report

Market Cap: CN¥40.2b

Haisco Pharmaceutical Group Balance Sheet Health

Financial Health criteria checks 5/6

Haisco Pharmaceutical Group has a total shareholder equity of CN¥4.2B and total debt of CN¥2.1B, which brings its debt-to-equity ratio to 49.4%. Its total assets and total liabilities are CN¥6.9B and CN¥2.7B respectively. Haisco Pharmaceutical Group's EBIT is CN¥380.0M making its interest coverage ratio -3.5. It has cash and short-term investments of CN¥1.3B.

Key information

49.4%

Debt to equity ratio

CN¥2.07b

Debt

Interest coverage ratio-3.5x
CashCN¥1.29b
EquityCN¥4.18b
Total liabilitiesCN¥2.73b
Total assetsCN¥6.91b

Recent financial health updates

Recent updates

Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares May Have Run Too Fast Too Soon

Nov 19
Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares May Have Run Too Fast Too Soon

Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

Aug 22
Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Jul 25
With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet

Jul 04
Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet

Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Jun 17
Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well

Mar 19
These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well

Risks To Shareholder Returns Are Elevated At These Prices For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Feb 27
Risks To Shareholder Returns Are Elevated At These Prices For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Financial Position Analysis

Short Term Liabilities: 002653's short term assets (CN¥2.9B) exceed its short term liabilities (CN¥1.4B).

Long Term Liabilities: 002653's short term assets (CN¥2.9B) exceed its long term liabilities (CN¥1.3B).


Debt to Equity History and Analysis

Debt Level: 002653's net debt to equity ratio (18.6%) is considered satisfactory.

Reducing Debt: 002653's debt to equity ratio has increased from 47.3% to 49.4% over the past 5 years.

Debt Coverage: 002653's debt is well covered by operating cash flow (24.8%).

Interest Coverage: 002653 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies